Form 4: Ventyx Biosciences Chief Medical Officer Acquires 3,000 Shares Through Employee Stock Purchase Plan

Mark S. Forman, Chief Medical Officer of Ventyx Biosciences, acquired 3,000 shares of common stock through the company's Employee Stock Purchase Plan at a price of $1.03 per share.

Summary

• Mark S. Forman, the Chief Medical Officer of Ventyx Biosciences, Inc., filed a Form 4 on May 16, 2025, reporting a change in beneficial ownership.
• The transaction involved the acquisition of 3,000 shares of Ventyx Biosciences common stock.
• The shares were acquired on May 15, 2025, through the company's 2021 Employee Stock Purchase Plan (ESPP).
• The purchase price was $1.03 per share, calculated as 85% of the closing price on May 15, 2025, as per the ESPP terms.
• Following the transaction, Mr. Forman directly owns 3,000 shares of Ventyx Biosciences common stock.

Sentiment

Score: 6

Explanation: Neutral sentiment. The document simply reports a transaction related to an employee stock purchase plan. It doesn't contain any information that would strongly indicate positive or negative sentiment.

Positives

• The acquisition of shares by a company officer can be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it shows confidence from a company officer.

Key Dates

Keywords

Form 4, Ventyx Biosciences, Mark S. Forman, Chief Medical Officer, Employee Stock Purchase Plan, Beneficial Ownership, VTYX, Stock Acquisition